Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.
Explores telomere syndromes, telomerase expression, end replication problems, telomere length during aging, defects in telomerase genes, and mouse models.
